AU2017376629B2 - Benzimidazole compounds as c-Kit inhibitors - Google Patents
Benzimidazole compounds as c-Kit inhibitors Download PDFInfo
- Publication number
- AU2017376629B2 AU2017376629B2 AU2017376629A AU2017376629A AU2017376629B2 AU 2017376629 B2 AU2017376629 B2 AU 2017376629B2 AU 2017376629 A AU2017376629 A AU 2017376629A AU 2017376629 A AU2017376629 A AU 2017376629A AU 2017376629 B2 AU2017376629 B2 AU 2017376629B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- cancer
- disorder
- alkyl
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2022201082A AU2022201082B2 (en) | 2016-12-15 | 2022-02-18 | Benzimidazole compounds as c-Kit inhibitors |
| AU2024200624A AU2024200624A1 (en) | 2016-12-15 | 2024-02-01 | Benzimidazole compounds as c-Kit inhibitors |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434839P | 2016-12-15 | 2016-12-15 | |
| US62/434,839 | 2016-12-15 | ||
| PCT/US2017/066299 WO2018112140A1 (en) | 2016-12-15 | 2017-12-14 | Benzimidazole compounds as c-kit inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022201082A Division AU2022201082B2 (en) | 2016-12-15 | 2022-02-18 | Benzimidazole compounds as c-Kit inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017376629A1 AU2017376629A1 (en) | 2019-07-04 |
| AU2017376629B2 true AU2017376629B2 (en) | 2021-11-25 |
Family
ID=60888754
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017376629A Ceased AU2017376629B2 (en) | 2016-12-15 | 2017-12-14 | Benzimidazole compounds as c-Kit inhibitors |
| AU2022201082A Ceased AU2022201082B2 (en) | 2016-12-15 | 2022-02-18 | Benzimidazole compounds as c-Kit inhibitors |
| AU2024200624A Abandoned AU2024200624A1 (en) | 2016-12-15 | 2024-02-01 | Benzimidazole compounds as c-Kit inhibitors |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022201082A Ceased AU2022201082B2 (en) | 2016-12-15 | 2022-02-18 | Benzimidazole compounds as c-Kit inhibitors |
| AU2024200624A Abandoned AU2024200624A1 (en) | 2016-12-15 | 2024-02-01 | Benzimidazole compounds as c-Kit inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11117883B2 (enExample) |
| EP (1) | EP3555066A1 (enExample) |
| JP (2) | JP7158383B2 (enExample) |
| KR (1) | KR20190092538A (enExample) |
| CN (3) | CN110291081B (enExample) |
| AU (3) | AU2017376629B2 (enExample) |
| BR (1) | BR112019012224A2 (enExample) |
| CA (1) | CA3047107A1 (enExample) |
| EA (1) | EA201991197A1 (enExample) |
| IL (3) | IL314209A (enExample) |
| MA (1) | MA53150A (enExample) |
| MX (2) | MX390348B (enExample) |
| WO (1) | WO2018112140A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110291081B (zh) * | 2016-12-15 | 2023-01-31 | 阿瑞雅德制药公司 | 作为c-kit抑制剂的苯并咪唑化合物 |
| CN109320503B (zh) * | 2018-12-10 | 2022-07-01 | 怀化学院 | 苯并咪唑炔胺类化合物的无金属一锅合成方法 |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| JP7711068B2 (ja) | 2019-12-24 | 2025-07-22 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and their uses |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| CA3235986A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Cd73 compounds |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4667056A1 (en) | 2021-12-22 | 2025-12-24 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| LT4245756T (lt) | 2022-03-17 | 2024-11-25 | Gilead Sciences, Inc. | Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | CD73 compounds |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| EP4695260A1 (en) | 2023-04-11 | 2026-02-18 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024300557A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2896620A1 (en) * | 2012-09-17 | 2015-07-22 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Alkynyl heteroaromatic ring compound and application thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| MXPA06002018A (es) * | 2003-08-21 | 2006-05-31 | Osi Pharm Inc | Bencimidazolilo n-sustituidos inhibidores de c-kit. |
| KR20070086865A (ko) * | 2004-12-01 | 2007-08-27 | 오에스아이 파마슈티컬스, 인코포레이티드 | Ｎ-치환된 벤즈이미다졸일 ｃ-ｋｉｔ 억제제 및 조합적인벤즈이미다졸 라이브러리 |
| UA94055C2 (en) * | 2005-08-30 | 2011-04-11 | Новартис Аг | Substituted benzimidazoles and methods of preparation |
| EP2762142A1 (en) * | 2009-10-30 | 2014-08-06 | ARIAD Pharmaceuticals, Inc. | Compositions for treating cancer |
| JP5740409B2 (ja) * | 2009-11-13 | 2015-06-24 | ジェノスコ | キナーゼ阻害剤 |
| CN103582478A (zh) * | 2011-04-07 | 2014-02-12 | 阿里亚德医药股份有限公司 | 治疗神经退行性疾病的方法和组合物 |
| CA2815506C (en) * | 2012-12-12 | 2018-12-11 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
| GB2522226A (en) * | 2014-01-17 | 2015-07-22 | Agency Science Tech & Res | Heteroaryl alkyne derivatives and uses thereof |
| CN110291081B (zh) * | 2016-12-15 | 2023-01-31 | 阿瑞雅德制药公司 | 作为c-kit抑制剂的苯并咪唑化合物 |
-
2017
- 2017-12-14 CN CN201780085539.3A patent/CN110291081B/zh not_active Expired - Fee Related
- 2017-12-14 JP JP2019531992A patent/JP7158383B2/ja active Active
- 2017-12-14 BR BR112019012224-9A patent/BR112019012224A2/pt not_active Application Discontinuation
- 2017-12-14 EA EA201991197A patent/EA201991197A1/ru unknown
- 2017-12-14 IL IL314209A patent/IL314209A/en unknown
- 2017-12-14 CN CN202211731994.5A patent/CN116178343A/zh active Pending
- 2017-12-14 MA MA053150A patent/MA53150A/fr unknown
- 2017-12-14 IL IL287517A patent/IL287517B2/en unknown
- 2017-12-14 CA CA3047107A patent/CA3047107A1/en active Pending
- 2017-12-14 CN CN202211737801.7A patent/CN116283910A/zh active Pending
- 2017-12-14 WO PCT/US2017/066299 patent/WO2018112140A1/en not_active Ceased
- 2017-12-14 AU AU2017376629A patent/AU2017376629B2/en not_active Ceased
- 2017-12-14 KR KR1020197020159A patent/KR20190092538A/ko not_active Abandoned
- 2017-12-14 EP EP17822994.4A patent/EP3555066A1/en not_active Withdrawn
- 2017-12-14 MX MX2019007080A patent/MX390348B/es unknown
- 2017-12-14 US US16/469,535 patent/US11117883B2/en not_active Expired - Fee Related
-
2019
- 2019-06-12 IL IL267260A patent/IL267260B2/en unknown
- 2019-06-14 MX MX2022002581A patent/MX2022002581A/es unknown
-
2021
- 2021-08-12 US US17/400,820 patent/US20220064144A1/en not_active Abandoned
-
2022
- 2022-02-18 AU AU2022201082A patent/AU2022201082B2/en not_active Ceased
- 2022-10-11 JP JP2022163367A patent/JP2022185110A/ja active Pending
-
2024
- 2024-02-01 AU AU2024200624A patent/AU2024200624A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2896620A1 (en) * | 2012-09-17 | 2015-07-22 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Alkynyl heteroaromatic ring compound and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110291081B (zh) | 2023-01-31 |
| IL287517B2 (en) | 2024-12-01 |
| IL287517A (en) | 2021-12-01 |
| JP2022185110A (ja) | 2022-12-13 |
| EP3555066A1 (en) | 2019-10-23 |
| CN110291081A (zh) | 2019-09-27 |
| WO2018112140A1 (en) | 2018-06-21 |
| CA3047107A1 (en) | 2018-06-21 |
| IL267260A (en) | 2019-08-29 |
| IL267260B (en) | 2022-10-01 |
| AU2022201082A1 (en) | 2022-03-10 |
| JP7158383B2 (ja) | 2022-10-21 |
| US20200039958A1 (en) | 2020-02-06 |
| EA201991197A1 (ru) | 2020-01-13 |
| IL314209A (en) | 2024-09-01 |
| IL287517B1 (en) | 2024-08-01 |
| MX2019007080A (es) | 2019-10-15 |
| MX390348B (es) | 2025-03-20 |
| IL267260B2 (en) | 2023-02-01 |
| MX2022002581A (es) | 2022-03-22 |
| AU2017376629A1 (en) | 2019-07-04 |
| CN116283910A (zh) | 2023-06-23 |
| JP2020503299A (ja) | 2020-01-30 |
| MA53150A (fr) | 2021-05-26 |
| US20220064144A1 (en) | 2022-03-03 |
| KR20190092538A (ko) | 2019-08-07 |
| CN116178343A (zh) | 2023-05-30 |
| AU2022201082B2 (en) | 2023-11-02 |
| AU2024200624A1 (en) | 2024-02-22 |
| US11117883B2 (en) | 2021-09-14 |
| BR112019012224A2 (pt) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022201082B2 (en) | Benzimidazole compounds as c-Kit inhibitors | |
| AU2022200741B2 (en) | Aminothiazole compounds as c-Kit inhibitors | |
| KR101959590B1 (ko) | c-KIT 키나제 억제제로서의 화합물 및 조성물 | |
| JP2022548095A (ja) | 接着分解剤及びその使用方法 | |
| TWI848925B (zh) | 肌旋蛋白激酶抑制劑 | |
| JP2020503271A (ja) | 造血前駆体キナーゼ１（ｈｐｋ１）阻害剤としてのアニリノピリミジンａｓ | |
| JP2017528491A (ja) | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体 | |
| JP2018512408A (ja) | Ｐｈｄ阻害剤としての縮合二環式ヘテロアリール誘導体 | |
| CA3202516A1 (en) | Aminothiazole compounds as c-kit inhibitors | |
| NZ795575A (en) | Benzimidazole compounds as c-Kit inhibitors | |
| NZ795572A (en) | Benzimidazole compounds as c-Kit inhibitors | |
| NZ795495A (en) | Aminothiazole compounds as c-Kit inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |